MAP2K7 and metastatic melanoma: For instance, the clinical trial (phase III) IMspire150, designed to assess combination therapies with BRAF and MEK inhibitors (vemurafenib, cobimetinib) and immune checkpoint therapy (atezolizumab) in BRAF V600-positive advanced or metastatic melanoma (n = 514), showed the value of the combined treatment.